Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical to develop treatments for cardiometabolic diseases.

This video explains the interactions within a protein cell network, what can go wrong, and how targeted drugs can alleviate these problems.

Other countries in Europe to lose eliminated status include Armenia, Austria, Azerbaijan, Spain, and Uzbekistan. Sustained ...

Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC ...

A new report has revealed that 83% of life sciences CEOs view Internet of Medical Things (IoMT) devices as the most important capability towards driving growth, accelerating R&D, and unlocking ...

The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...

The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.

With a market cap of around $23bn, Revolution has seen its stock climb over the year on the back of its promising oncology portfolio. Credit: Tada Images via Shutterstock.com. Merck & Co (MSD) is no ...

Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for ...

Daiichi Sankyo and AstraZeneca’s Enhertu has received approval from China’s NMPA for adult patients with locally advanced or ...